In order to evaluate lapatinib access into normal brain and brain metastases, a positron emission tomography (PET) study was performed with carbon-11 radiolabelled lapatinib ([11C]lapatinib) in patients with Her-2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.